home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

118.10 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Mar 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings? ↗

February 03, 2025

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is...

Via Benzinga

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Via Benzinga

Market Whales and Their Recent Bets on MRK Options ↗

January 31, 2025

Via Benzinga

5 Top Stocks to Buy in February 2025 ↗

January 31, 2025

All of them have great upside.

Via The Motley Fool

A Closer Look at Merck & Co's Options Market Dynamics ↗

January 29, 2025

Via Benzinga

Forecasting The Future: 12 Analyst Projections For Merck & Co ↗

January 28, 2025

Via Benzinga

Balancing Dividends and Fundamentals: The Case of NYSE:MRK. ↗

January 28, 2025

Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics.

Via Chartmill

Why This Beaten-Down Stock Is a Buy in 2025 and Beyond ↗

January 27, 2025

Via The Motley Fool

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

January 31, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

January 30, 2025

From Merck & Co., Inc.

Via Business Wire

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

NYSE:MRK is probably undervalued for the fundamentals it is displaying. ↗

January 23, 2025

MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.

Via Chartmill

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗

January 29, 2025

The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr.

Via Investor's Business Daily

Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization

January 28, 2025

From Merck & Co., Inc.

Via Business Wire

FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)

January 27, 2025

From Merck & Co., Inc.

Via Business Wire

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗

January 24, 2025

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Via Benzinga

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗

January 24, 2025

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Via Investor's Business Daily

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

January 24, 2025

From Merck & Co., Inc.

Via Business Wire

RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing ↗

January 23, 2025

Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.

Via Benzinga

Topics Lawsuit

3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗

January 23, 2025

Via The Motley Fool

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗

January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Via Benzinga

Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines ↗

January 22, 2025

Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine.

Via Investor's Business Daily

Topics Artificial Intelligence

Why Summit Therapeutics Stock Is Jumping Today ↗

January 21, 2025

Via The Motley Fool

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others ↗

January 20, 2025

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, Merck & Co., Inc., and QUALCOMM Incorporated, as well as two micro-cap stocks CSP Inc. and AMCON...

Via Talk Markets

Topics Stocks / Equities

Healthcare And Biotech Stocks Lag The Market Again ↗

January 20, 2025

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Via Talk Markets

Topics Stocks / Equities

AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion ↗

January 18, 2025

Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com